This week's must-know community updates, latest research & events
March 13, 2025 • Estimated Reading Time: 1 minute
New This Week
Exciting news! There is now a new section featuring clinical trials that are actively recruiting patients. This highly requested addition gives you direct access to cutting-edge research opportunities that could shape the future of treatment.
Stay informed about potentially life-changing studies and let us know what you think by replying to this email!
In a comprehensive review by Pathology et al. (2025), the prevalence of alloimmunization in patients with sickle cell disease in the Middle East was found to be around 14%. Alloimmunization is a condition where the immune system reacts against foreign antigens after a blood transfusion. The study analyzed data from 19 studies including 3,867 patients. The most common antibodies developed were against the Kell, RhE, and RhD antigens, which are specific types of proteins on the surface of red blood cells.
The research also identified several risk factors for developing alloimmunization, such as being older, female, having a higher number of transfusions, and undergoing a splenectomy (removal of the spleen). Interestingly, the review highlighted that retrospective studies reported a higher prevalence of alloimmunization compared to cross-sectional studies. Pathology et al. emphasized the importance of matching blood transfusions not only for ABO and Rh types but also for the K antigen to reduce the risk of alloimmunization in patients with sickle cell disease.
Clinical Trials
This is a list of upcoming or ongoing clinical trials that are actively recruiting and have been listed or updated in the last two weeks:
More Info 
Add to Calendar